Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Medical TechnologyNOCD’s strategic move to create a parent brand, Noto, marks a significant expansion of its virtual mental health services. With the acquisition of Rebound Health, it aims to address complex conditions like PTSD alongside OCD, reflecting broader trends in digital mental health care innovation.
Daniel ChoJan 29, 2026
Biotech InnovationEmerging biotech Baseline Therapeutics is positioning itself as a challenger in the development of GLP-1–based therapies for alcohol use disorder. Their lead asset, BT-001, is set to enter late-stage clinical trials, marking a significant step in tackling addiction through novel mechanisms.
Daniel ChoJan 27, 2026
Regulatory & PolicyThe pediatric priority review voucher program has been a crucial incentive for biotechs developing therapies for rare diseases, especially those affecting children. The program's lapse puts at risk significant financial and developmental momentum in the sector, with ramifications for patients and companies alike.
Daniel ChoJan 26, 2026
AI in Drug DiscoveryMenopause and perimenopause have historically been areas of healthcare with limited personalized treatment options. The NIH-backed Amissa startup aims to change that narrative by leveraging artificial intelligence to aggregate and analyze data, providing improved care strategies for women undergoing these life stages. This detailed exploration delves into the technology behind Amissa's platform and its potential impact on women's health.
Daniel ChoJan 22, 2026